Dianne Pulte, MD, Kelly J. Norsworthy, MD, Laura Fernandes, Bindu Kanapuru, MD, Catherine Lerro, Fatima Rizvi, Jonathon Vallejo, Ph.D., Kun Wang, PhD, Joseph Wynne, MD, PhD, Anna Barcellos, Andrew J. Belli, Eric Hansen, Thomas Gwise, Ph.D., Paul Kluetz, Angelo De Claro, Ching-Kun Wang and Donna Rivera
Clinical trials are essential to establish the efficacy and safety of medical products; however, clinical trials may not always be representative of or generalizable to the intended patient population. Notably, patients with comorbidities, older adults, and patients from racial and ethnic groups are often under-represented in clinical trials for acute myeloid leukemia (AML) (Bierenbaum et al, Leuk Res, 2012). Real-world data (RWD) can provide insight into the utilization, effectiveness, and safety of treatment regimens in routine clinical practice and has demonstrated usefulness in understanding the current treatment landscape. The objective of this study was to describe patient characteristics and treatment patterns in the first-line setting among a real-world cohort of adult patients with ND-AML in the US.